Xifaxan Ibsd denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for xifaxan ibsd are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Applies Quantity Limits to Xifaxan (rifaximin) for IBS-D

UnitedHealthcare's quantity-limit programs restrict coverage to a defined supply per dispensing period for Xifaxan in IBS-D. These limits are set by UHC's pharmacy benefit management policies and may not align with the prescriber's recommended course of treatment or the FDA-approved dosing regimen. When a physician prescribes a quantity that exceeds UHC's limit — even if that quantity matches the FDA-approved label — coverage will be denied for the excess units unless a quantity-limit exception is approved.

Quantity-limit exceptions are routinely granted when clinical documentation demonstrates that the prescribed quantity is consistent with the FDA-approved labeling and the patient's specific clinical need.

## Your Appeal Rights

• Quantity-limit exception / internal appeal (ERISA §503): File a written request for a quantity-limit exception alongside a formal internal appeal. The two can be submitted together.
• External review (ACA §2719): If the exception and internal appeal are denied, independent external review is available. File within the four-month window from the final internal denial. The external reviewer's determination is binding on UHC.
• Expedited review: Request expedited processing if treatment delay would be clinically harmful.

## Documentation to Gather

1. FDA prescribing label — obtain the current label for Xifaxan; highlight the approved indication for IBS-D and the recommended treatment course. Demonstrate that the prescribed quantity aligns with the label. 2. Prescriber medical-necessity letter — the prescriber should explain the clinical rationale for the prescribed quantity, referencing the FDA-approved course of treatment and the patient's response history. 3. Treatment history — prior courses of treatment (type, duration, outcomes) to establish the context for the current prescription. 4. UHC quantity-limit policy — request UHC's current quantity-limit criteria for Xifaxan in writing; address each criterion in the appeal. 5. Pharmacy records — confirm what has been dispensed and what is being denied, to frame the exact scope of the appeal.

## Criteria-Mapping Structure

A focused quantity-limit appeal should map the FDA label's approved treatment parameters against UHC's quantity-limit policy:

| UHC Quantity-Limit Criterion | Supporting Documentation | |---|---| | Quantity consistent with FDA-approved labeling | FDA label, treatment course section highlighted | | Clinical necessity for prescribed quantity | Prescriber letter with patient-specific rationale | | Prior treatment history | Pharmacy records + chart notes with dates |

Request UHC's full quantity-limit criteria document before filing so the appeal explicitly addresses each listed requirement.